Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52

Immunogenetics

Volumn 43, Issue 6, 1996, Pages 392-397

  Verreck, Frank A W ^a   Van De Poel, Anja ^a   Drijfhout, Jan Wouter ^a   Amons, Reinout ^b   Coligan, John E ^c   Koning, Frits ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLUTAMINE; GLYCINE; HLA DR ANTIGEN; HLA DR1 ANTIGEN; VALINE;

ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; HUMAN; HYDROGEN BOND; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AMINO ACID SEQUENCE; CELL LINE; CONSENSUS SEQUENCE; GLYCINE; HLA-DR ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; VALINE;

EID: 0029875681     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02199809     Document Type: Article

References (28)

1. Busch, R., Hill, C. M., Hayball, J. D., Lamb, J. R., and Rothbard, J. B. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding. J Immunol 147: 1292-1298, 1991
2. Chicz, R. M., Urban, R. G., Gorga, J. C., Vignali, D. A., Lane, W. S., and Strominger, J. L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178: 27-47, 1993
3. Davenport, M. P., Quinn, C. L., Chicz, R. M., Green, B. N., Willis, A. C., Lane, W. S., Bell, J. I., and Hill, A. V. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effect of the dimorphism at position 86 of the HLA-DRβ chain. Proc Natl Acad Sci USA 92: 6567-6571, 1995
4. De Bueger, M., Verreck, F., Blokland, E., Drijfhout, J. W., Amons, R., Koning, F., and Goulmy, E. Isolation of an HLA-A2.1 extracted human minor histocompatibility peptide. Eur J Immunol 23: 614-618, 1993
5. De Koster, H. S., van Rood, J. J., and Termijtelen, A. HLA-DR peptide-induced alloreactive T cell lines reveal an HLA-DR sequence that can be both "dominant" and "cryptic": evidence for allele-specific processing. Eur J Immunol 22: 1531-1539, 1992
6. Demotz, S., Barbey, C., Corradin, G., Amoroso, A., and Lanzavecchia, A. The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur J Immunol 23: 425-432, 1993
7. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G., and Rammensee, H. G. Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39: 230-242, 1994
8. Geluk, A., van Meijgaarden, K. E., Janson, A. A., Drijfhout, J. W., Meloen, R. H., de Vries, R. R., and Ottenhoff, T. H. Functional analysis of DR17(DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J Immunol 149: 2864-2871, 1992
9. Hammer, J., Takacs, B., and Sinigaglia, F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 176: 1007-1013, 1992
10. Hammer, J., Valsasnini, P., Tolba, K., Bolin, D., Higelin, J., Takacs, B., and Sinigaglia, F. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74: 197-203, 1993
11. Johnson, A. H., Fang-Tang, T., Cowell, V., and Katovich-Hurley, C. The impact of naturally occurring DR3 microvariants, DRw17 and DRw18, on T-cell allorecognition. Hum Immunol 32: 46-55, 1991
12. Koning, F., Schreuder, M., Giphart, M., and Bruning, H. A mouse monoclonal antibody detecting a DR-related MT2-like specificity: serology and biochemistry. Hum Immunol 9: 221, 1984
13. Krieger, J. I., Karr, R. W., Grey, H. M., Yu, W., O'Sullivan, D., Batovsky, L., Zheng, Z., Colon, S. M., Gaeta, F. C. A., Sidney, J., Albertson, M., del Guerico, M., Chesnut, R. W., and Sette, A. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recogntion. J Immunol 146: 2331-2340, 1991
14. Kropshofer, H., Max, H., Muller, C. A, Hesse, F., Stevanović, S., Jung, G., and Kalbacher, H. Self-peptide released from class II HLA-DR1 exhibits a Hydrophobic two-residue contact motif. J Exp Med 175: 1799-1803, 1992
15. Kropshofer, H., Max, H., Halder, T., Kalbus, M., Muller, C. A., and Kalbacher, H. Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming. J Immunol 151: 4732-4742, 1993
16. Lang, B., LoGalbo, P. R., Sanchez, B., and Winchester, R. HLA-Dw14 and HLA-DR2 haplotypes share a functional determinant recognized by a human alloreactive T-cell clone. Hum Immunol 23: 59-70, 1988
17. Malcherek, G., Falk, K., Rötzschke, O., Rammensee, H. G., Stevanovic, S., Gnau, V., Jung, G., and Melms, A. Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. Int Immunol 5: 1229-1237, 1993
18. Marshall, K. W., Liu, A. F., Canales, J., Perahia, B., Jorgensen, B., Gantzos, R. D., Aguilar, B., Devaux, B., and Rothbard, J. B. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J Immunol 152: 4946-4957, 1994
19. Newcomb, J. R. and Cresswell, P. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers. J Immunol 150: 499-507, 1993
20. Ong, B., Willcox, N., Wordsworth, P., Beeson, D., Vincent, A., Altmann, D., Lanchbury, J. S. S., Harcourt, G. C., Bell, J. I., and Newsom-Davis, J. Critical role for the Val/Gly86 HLA-DRβ86 dimorphism in autoantigen presentation to human T cells. Proc Natl Acad Sci USA 88: 7343-7347, 1991
21. Rammensee, H. G., Friede, T., and Stevanović, S. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228, 1995
22. k crossreacting with human DR molecule. Eur J Immunol 13: 106-111, 1983
23. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L., and Wiley, D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368: 215-221, 1994
24. Verreck, F. A., Termijtelen, A., and Koning, F. HLA-DR beta chain residue 86 controls DR alpha beta dimer stability. Eur J Immunol 23: 1346-1350, 1993
25. Verreck, F. A. W., Elferink, D., Vermeulen, C. J., Amons, R., Breedveld, F., de Vries, R. R. P., and Koning, F. DR4Dw4/DR53 molecules contain a peptide from the autoantigen calreticulin. Tissue Antigens 45: 270-275, 1995
26. Verreck, F. A. W., Vermeulen, C., Van de Poel, A., Jorritsma, P., Amons, R., Coligan, J. E., Drijfhout, J. W., and Koning, F. The generation of SDS stable HLA DR dimers is independent of efficient peptide binding. Im Immunol 8, in press
27. Vogt, A. B., Kropshofer, H., Kalbacher, H., Kalbus, M., Rammensee, H. G., Coligan, J. E., and Martin, R. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 153: 1665-1673, 1994
28. Zeliszewski, D., Tiercy, J.-M., Dorval, I., Kaplan, C., March, B., and Sterkers, G. DR-restricted T-cell locus DRB3 (DRw52c) or locus DRB1. Hum Immunol 28: 345-353, 1990